RxDoctor Payments Data

Alice Lim, MD

Family Medicine · Houston, TXNPI 1912956491

Payments from drug & device makers

$3,489in general payments, 2019–2025

Across 202 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$787
  • AstraZeneca$658
  • Amgen$415
  • Boehringer Ingelheim$369
  • Lilly USA, LLC$291
  • Amarin Pharma, Inc.$174
  • plus $796 from 20 others

What the payments were for

  • Food & beverage$3,476100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,489 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$67,698
Medicare patients
105
Services billed
1,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$71,825
Synjardy XrEmpagliflozin/Metformin Hcl44$67,464
RybelsusSemaglutide29$55,728
OzempicSemaglutide24$51,250
FarxigaDapagliflozin Propanediol33$40,319
Janumet XrSitagliptin Phos/Metformin Hcl26$31,124
Xigduo XrDapaglifloz Propaned/Metformin19$28,802
TradjentaLinagliptin17$27,331
ProliaDenosumab12$20,844
VascepaIcosapent Ethyl36$19,721
Tresiba Flextouch U-200Insulin Degludec15$16,840
Tresiba Flextouch U-100Insulin Degludec12$13,276
EliquisApixaban12$11,817
Olmesartan Medoxomil155$2,827
Losartan Potassium261$2,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$369$166,620110 claims
Novo NordiskRybelsus, Ozempic$787$106,97853 claims
AstraZenecaFarxiga$658$40,31933 claims
MerckJanumet Xr$28$31,12426 claims
AmgenProlia$415$20,84412 claims
PfizerEliquis$24$11,81712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →